References from scientific journals

Myelodysplastic syndromes: Contemporary review and how we treat.

Gangat N, Patnaik MM, Tefferi A. Gangat N, et al. Am J Hematol. 2016 Jan;91(1):76-89. doi: 10.1002/ajh.24253. Am J Hematol. 2016. PMID: 26769228 Free article. Review.

Currently Food and Drug administration (FDA)-approved drugs for the treatment of MDS are not curative and their effect on survival is limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). ...
Currently Food and Drug administration (FDA)-approved drugs for the treatment of MDS are not curative and their effect on survival is limite …

Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression.

Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. Seelan RS, et al. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18. Drug Metab Rev. 2018. PMID: 29455551 Review.


Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Cogle CR, et al. Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Oncologist. 2015. PMID: 26463870 Free PMC article. Review.

Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results …
Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This …

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.

Christman JK. Christman JK. Oncogene. 2002 Aug 12;21(35):5483-95. doi: 10.1038/sj.onc.1205699. Oncogene. 2002. PMID: 12154409 Review.


Decitabine.

Hackanson B, Daskalakis M. Hackanson B, et al. Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18. Recent Results Cancer Res. 2014. PMID: 24756800 Review.

Besides 5-azacytidine (azacitidine, Vidaza), 5-aza-2'-deoxycytidine (decitabine, Dacogen) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and i …
Besides 5-azacytidine (azacitidine, Vidaza), 5-aza-2'-deoxycytidine (decitabine, Dacogen) is the most widely used inhibitor of DNA me …

Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.

He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J. He PF, et al. Oncotarget. 2017 Jun 20;8(25):41498-41507. doi: 10.18632/oncotarget.17241. Oncotarget. 2017. PMID: 28489568 Free PMC article. Review.


Decitabine.

Daskalakis M, Blagitko-Dorfs N, Hackanson B. Daskalakis M, et al. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. Recent Results Cancer Res. 2010. PMID: 20072836 Review.

The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically sil …
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, ar …

5-Azacytidine/Azacitidine.

Müller A, Florek M. Müller A, et al. Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11. Recent Results Cancer Res. 2010. PMID: 20072837 Review.


Azacitidine.

National Toxicology Program. National Toxicology Program. Rep Carcinog. 2011;12:56-7. Rep Carcinog. 2011. PMID: 21829253 Free article. No abstract available.


A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.

Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, Murad MH, Al-Kali A. Almasri J, et al. Syst Rev. 2018 Sep 19;7(1):144. doi: 10.1186/s13643-018-0805-7. Syst Rev. 2018. PMID: 30227896 Free PMC article.

BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). ...CONCLUSIONS: Azacitidine and decitabine are both associated with improved outcomes compared to BSC. ...
BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndro …